Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Recommendation of "Hold" from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $380.00.

A number of equities research analysts have recently commented on MEDP shares. Redburn Atlantic started coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 price target on the stock. TD Cowen cut their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Jefferies Financial Group cut shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. William Blair restated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MEDP. State of Michigan Retirement System raised its position in Medpace by 1.8% in the first quarter. State of Michigan Retirement System now owns 5,699 shares of the company's stock worth $2,303,000 after acquiring an additional 100 shares during the period. Norden Group LLC lifted its stake in shares of Medpace by 488.0% during the 1st quarter. Norden Group LLC now owns 29,480 shares of the company's stock valued at $11,914,000 after buying an additional 24,466 shares in the last quarter. Arcus Capital Partners LLC lifted its stake in shares of Medpace by 15.7% during the 1st quarter. Arcus Capital Partners LLC now owns 965 shares of the company's stock valued at $390,000 after buying an additional 131 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Medpace by 32.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 4,308 shares of the company's stock valued at $1,741,000 after buying an additional 1,055 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Medpace by 36.5% during the 1st quarter. Van ECK Associates Corp now owns 11,201 shares of the company's stock valued at $4,527,000 after buying an additional 2,996 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.1 %

Shares of NASDAQ MEDP traded up $0.41 on Tuesday, reaching $329.76. 254,278 shares of the company's stock traded hands, compared to its average volume of 274,436. Medpace has a 12 month low of $239.00 and a 12 month high of $459.77. The business's 50 day simple moving average is $350.20 and its two-hundred day simple moving average is $380.49. The company has a market cap of $10.22 billion, a price-to-earnings ratio of 33.47, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million for the quarter, compared to analysts' expectations of $540.99 million. During the same quarter in the prior year, the company posted $2.22 earnings per share. The business's revenue for the quarter was up 8.3% on a year-over-year basis. Analysts forecast that Medpace will post 11.77 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.